KIM-1在晚期乳头状与透明细胞肾细胞癌中的表达与预后价值
CALYPSO前瞻性多臂试验探索KIM-1在晚期透明细胞肾细胞癌(ccRCC)和乳头状肾细胞癌(pRCC)中的意义。结果显示pRCC患者基线KIM-1中位浓度高于ccRCC(7835 vs 5470 pg/ml,p=0.05),系统治疗后两者KIM-1均下降(ccRCC -59.2%,pRCC -32%)。在ccRCC中,高基线KIM-1与更短总生存(OS)相关(HR 1.77;95%CI 1.15-2.72;p=0.01),治疗中KIM-1升高与更差无进展生存(PFS)(HR 1.7;95%CI 1.13-2.58;p=0.01)和OS(HR 1.95;95%CI 1.23-3.08;p=0.004)相关。
要点
- pRCC患者基线KIM-1中位浓度高于ccRCC(7835 vs 5470 pg/ml,p=0.05)。
- ccRCC中高基线KIM-1与更短OS独立相关(HR 1.77,p=0.01)。
- ccRCC治疗中KIM-1升高与更差PFS和OS相关。
核心结论
- 探索性分析支持KIM-1在晚期ccRCC和pRCC中作为潜在生物标志物的价值。
研究设计与样本
- CALYPSO(NCT02819596)为前瞻性多臂试验,评估度伐利尤单抗单药或联合替西木单抗或Savolitinib在转移性ccRCC和pRCC中的疗效。
- 共纳入123例ccRCC和31例pRCC患者,基线及治疗中检测循环KIM-1水平。
- 主要终点为探索pRCC中KIM-1水平是否升高,所有分析均为探索性,p值为名义值。
主要发现
- pRCC患者KIM-1中位浓度高于ccRCC(7835 vs 5470 pg/ml,p=0.05)。
- 系统治疗后ccRCC和pRCC的KIM-1水平分别下降59.2%和32%。
- pRCC中影像学缓解者基线KIM-1水平显著更低(p=0.025)。
- ccRCC中高基线KIM-1与更短OS相关(HR 1.77;95%CI 1.15-2.72;p=0.01)。
- ccRCC治疗中KIM-1升高与更差PFS(HR 1.7;95%CI 1.13-2.58;p=0.01)和OS(HR 1.95;95%CI 1.23-3.08;p=0.004)相关。
局限性
- 分析为探索性,p值为名义值,未校正多重比较。
- 样本量有限(ccRCC 123例,pRCC 31例),需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney injury molecule 1 (KIM-1) is a promising biomarker in adjuvant clear cell renal cell carcinoma (ccRCC), but its relevance in advanced ccRCC or papillary RCC (pRCC) remains unclear. CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Circulating KIM-1 levels were measured at baseline and on-treatment. The primary endpoint was to explore if KIM-1 levels were raised in pRCC. Analyses were exploratory and p values were nominal. KIM-1 was measured in 123 patients with ccRCC and 31 patients with pRCC. Higher median concentrations occurred in pRCC compared to ccRCC (7835 vs 5470 pg/ml, p = 0.05). Reductions in KIM-1 levels occurred with systemic therapy in both ccRCC and pRCC (-59.2% and -32% respectively). In pRCC, radiological responders had significantly lower baseline KIM-1 levels (p = 0.025). In ccRCC, high baseline KIM-1 levels were associated with significantly shorter overall survival (OS) (hazard ratio [HR] 1.77; 95% CI, 1.15-2.72; p = 0.01). Also, an increase in KIM-1 during therapy was linked to worse progression-free survival (HR 1.7; 95% CI, 1.13-2.58; p = 0.01) and OS (HR 1.95; 95% CI, 1.23-3.08; p = 0.004) in ccRCC. This exploratory analysis supports the utility of KIM-1 in advanced ccRCC and pRCC.
引用
- Coca Membribes S, Xu W, Suárez C, et al. KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma. Eur Urol. 2026. PMID: 41934036. doi:10.1016/j.eururo.2026.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。